The primary goal of the present study is to assess controversial results regarding previous studies about the anti-tumour effect of MSCs and, more precisely, examine whether equipped MSCs with TLR3/4 agonists can potentiate the anti-tumour effect of MSCs. The gene discussed is TLR3; the disease is neoplasm.